Skip to main content

Xerava Side Effects

Generic name: eravacycline

Medically reviewed by Last updated on Nov 9, 2023.

Note: This document contains side effect information about eravacycline. Some dosage forms listed on this page may not apply to the brand name Xerava.

Applies to eravacycline: intravenous powder for solution.

Serious side effects of Xerava

Along with its needed effects, eravacycline (the active ingredient contained in Xerava) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking eravacycline:

Less common


Other side effects of Xerava

Some side effects of eravacycline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common


For Healthcare Professionals

Applies to eravacycline: intravenous powder for injection.


The most common side effects were infusion site reactions, nausea, and vomiting. This drug was discontinued due to side effects in 2% of patients (compared to 2% for comparator); discontinuation was most often due to gastrointestinal disorders.[Ref]


Common (1% to 10%): Hypotension, thrombophlebitis (includes thrombophlebitis, infusion site thrombosis), phlebitis (includes phlebitis, infusion site phlebitis, superficial phlebitis, injection site phlebitis)

Frequency not reported: Palpitations


Uncommon (0.1% to 1%): Rash, hyperhidrosis

Tetracycline class:

-Frequency not reported: Photosensitivity


Common (1% to 10%): Nausea, vomiting, diarrhea

Uncommon (0.1% to 1%): Pancreatitis

Frequency not reported: Acute pancreatitis, pancreatic necrosis, increased amylase, increased lipase

Antibiotic class:

-Uncommon (0.1% to 1%): Treatment-related diarrhea

-Frequency not reported: Pseudomembranous colitis


Frequency not reported: Prolonged activated partial thromboplastin time, decreased WBC count, neutropenia


Uncommon (0.1% to 1%): Increased ALT, increased AST, hyperbilirubinemia

Frequency not reported: Increased GGT


Uncommon (0.1% to 1%): Hypersensitivity


Common (1% to 10%): Infusion site reactions (includes catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, superficial phlebitis, thrombophlebitis, vessel puncture site swelling, injection site pain/discomfort, injection site swelling/inflammation), infusion site phlebitis

Uncommon (0.1% to 1%): Infusion site thrombosis, vessel puncture site erythema, infusion site hypoesthesia


Frequency not reported: Hypocalcemia

Nervous system

Uncommon (0.1% to 1%): Dizziness, headache

Frequency not reported: Dysgeusia

Tetracycline class:

-Frequency not reported: Pseudotumor cerebri


Common (1% to 10%): Wound dehiscence

Frequency not reported: Chest pain

Antibiotic class:

-Frequency not reported: Overgrowth of nonsusceptible organisms (including fungi)

Tetracycline class:

-Frequency not reported: Antianabolic action (leading to increased BUN, azotemia, acidosis, hyperphosphatemia)


Frequency not reported: Anxiety, insomnia, depression


Frequency not reported: Decreased renal clearance of creatinine


Frequency not reported: Pleural effusion, dyspnea

Frequently asked questions


1. Product Information. Xerava (eravacycline). PAION Deutschland GmbH. 2022.

2. Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.